Cipla will replace Sun Pharmaceuticals in Sensex from May 3, 2010. The sole pharmaceutical company featuring in the benchmark index will see the weightage of the sector decline marginally to 0.66% from 1% earlier in the Sensex.
The index committee of the Bombay Stock Exchange (BSE) in its meeting held on March 19 has decided to revise the composition of its indices.
Sun Pharmaceuticals with Rs 35,131 crore market capitalisation is on top of the market cap ranking in pharmaceutical companies ahead of Cipla, which current market cap stands at Rs 26,781 crore.
Sun Pharmaceutical was entered in the Sensex in place of Mahindra Satyam (formerly Satyam Computer Services) on January 12, 2010.
The committee has also revised the composites of three broader indices – BSE-100, BSE-200 and BSE-500 index w.e.f March 29.
Lupin, NHPC, Shriram Transport Finance Company and UltraTech Cement included in BSE-100 index in place of Asian Paints, Glaxosmithkline Pharmaceuticals, Bajaj Finserv and Mahanagar Telephone Nigam.
The BSE-200 index replaces 16 companies and BSE-500 index has reshuffled 32 companies, the BSE said in its statement.
Top Section
Explore Business Standard